Metformin for the Improvement of Comorbid Depression Symptoms in Diabetic Patients: A Systematic Review.
antidiabetic drugs
depression
diabetes mellitus
high blood glucose levels
metformin
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
27
07
2022
accepted:
30
08
2022
entrez:
3
10
2022
pubmed:
4
10
2022
medline:
4
10
2022
Statut:
epublish
Résumé
Diabetes mellitus and depression are chronic debilitating disorders and can occur comorbidly. They are thought to be linked not only through environmental and behavioral factors but through molecular mechanisms as well. Antidepressant medication and psychological therapy, standard treatments for depressive symptoms in Type 2 diabetes mellitus, are linked to high rates of treatment failure and non-adherence; therefore, understanding the molecular mechanisms linking diabetes and depression could lead to discovering new targets and developing novel therapeutics. Metformin is considered a first-line anti-diabetic medication for Type 2 diabetes mellitus, and several studies have discussed its antidepressant effect. Metformin is thought to promote neurogenesis, enhance spatial memory function and protect the brain against oxidative imbalance. This systematic review aims to compile information on metformin's effect on depression symptoms and assess current knowledge on the relationship between depression and diabetes. After reviewing several studies, we concluded that metformin might help treat comorbid depression in diabetic patients, but before it can be recommended as a depression medication, more extensive and better-designed trials are needed.
Identifiants
pubmed: 36185927
doi: 10.7759/cureus.28609
pmc: PMC9523099
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e28609Informations de copyright
Copyright © 2022, Hamal et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Clin Psychiatry. 2022 Feb 1;83(2):
pubmed: 35120288
Front Psychiatry. 2018 Oct 02;9:450
pubmed: 30333763
Patient Prefer Adherence. 2020 Apr 15;14:737-746
pubmed: 32346286
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Cochrane Database Syst Rev. 2017 Sep 27;9:CD011469
pubmed: 28954185
Brain Behav. 2021 Feb;11(2):e01981
pubmed: 33274609
Pharmacol Res Perspect. 2019 Nov 21;7(6):e00536
pubmed: 31768258
Int J Mol Sci. 2020 Sep 22;21(18):
pubmed: 32971941
Res Integr Peer Rev. 2019 Mar 26;4:5
pubmed: 30962953
Korean J Fam Med. 2018 May;39(3):137-146
pubmed: 29788701
BMJ Open. 2016 Dec 8;6(12):e011458
pubmed: 27932337
Psychoneuroendocrinology. 2022 Jun;140:105715
pubmed: 35338947
Naunyn Schmiedebergs Arch Pharmacol. 2020 Aug;393(8):1391-1404
pubmed: 32077986
Saudi Pharm J. 2020 Mar;28(3):329-337
pubmed: 32194335
Cochrane Database Syst Rev. 2017 Jun 15;6:CD003804
pubmed: 28617932
Int J Endocrinol. 2020 Jul 24;2020:9879517
pubmed: 32774367
Psychoneuroendocrinology. 2018 Aug;94:91-103
pubmed: 29775878
BMC Med Res Methodol. 2014 Apr 01;14:45
pubmed: 24690082
BMJ. 2017 Sep 21;358:j4008
pubmed: 28935701
J Diabetes Complications. 2017 Apr;31(4):679-686
pubmed: 28190681
Contemp Clin Trials. 2017 Sep;60:113-124
pubmed: 28642211
Life (Basel). 2021 Aug 11;11(8):
pubmed: 34440563
Neurotherapeutics. 2020 Oct;17(4):1897-1906
pubmed: 32500486
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):1179-1186
pubmed: 32673838
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Dec 20;95:109720
pubmed: 31352032